A detailed history of O'Brien Greene & Co. Inc transactions in P Lx Pharma Inc. stock. As of the latest transaction made, O'Brien Greene & Co. Inc holds 27,000 shares of PLXP stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,000
Previous 27,000 -0.0%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
N/A
5,000 Added 22.73%
27,000 $0
Q2 2023

Aug 15, 2023

SELL
$0.0 - $0.36 $0 - $15,840
-44,000 Reduced 66.67%
22,000 $0
Q2 2023

Jul 20, 2023

BUY
$0.0 - $0.36 $0 - $15,840
44,000 Added 200.0%
66,000 $0
Q4 2022

Feb 02, 2023

SELL
$0.15 - $0.63 $6,753 - $28,362
-45,020 Reduced 67.17%
22,000 $4,000
Q3 2022

Nov 09, 2022

BUY
$0.52 - $3.08 $23,233 - $137,614
44,680 Added 200.0%
67,020 $44,000
Q2 2022

Aug 11, 2022

SELL
$1.9 - $4.18 $72,200 - $158,840
-38,000 Reduced 62.98%
22,340 $54,000
Q4 2021

Feb 08, 2022

SELL
$7.69 - $19.66 $15,380 - $39,320
-2,000 Reduced 3.21%
60,340 $483,000
Q3 2021

Nov 12, 2021

BUY
$12.22 - $21.28 $761,794 - $1.33 Million
62,340 New
62,340 $1.2 Million

Others Institutions Holding PLXP

About PLx Pharma Inc.


  • Ticker PLXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,137,700
  • Description
  • PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...
More about PLXP
Track This Portfolio

Track O'Brien Greene & Co. Inc Portfolio

Follow O'Brien Greene & Co. Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Brien Greene & Co. Inc, based on Form 13F filings with the SEC.

News

Stay updated on O'Brien Greene & Co. Inc with notifications on news.